Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions
RecruitingOBSERVATIONAL
Enrollment
1,200
Participants
Timeline
Start Date
June 1, 2018
Primary Completion Date
June 30, 2025
Study Completion Date
July 30, 2025
Conditions
Hepatocellular Carcinoma (HCC)
Trial Locations (1)
Unknown
RECRUITING
Zhongda Hospital, Nanjing
All Listed Sponsors
lead
Zhongda Hospital
OTHER
NCT06881446 - Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions | Biotech Hunter | Biotech Hunter